Treatment
Rivaroxaban clinical trials
We’re tracking 56 recruiting studies that include Rivaroxaban, each written for real people, not researchers, below.
Recruiting studies
- NCT07404436RecruitingPhase 4
Blood thinner to prevent clots in kidney disease
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Beijing, Beijing MunicipalityAges 18–80 - NCT05638867RecruitingPhase 4
Blood thinner choice guided by risk score for heart attack patients
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
Beijing, Beijing MunicipalityAges 18–75 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Birmingham, AlabamaAges 18 years+ - NCT06650501RecruitingPhase 4
Comparing two blood thinners for staph bloodstream infections
This study compares two types of blood thinners (dabigatran vs. a common Xa inhibitor like apixaban) in people with a staph infection in their blood. The goal is to see which is safer and works better.
Montreal, QuebecAges 18 years+ - NCT06961630RecruitingEarly Phase 1
Heart protection after surgery
This trial tests if a personalized approach with blood thinners and statins can reduce heart risks after non-cardiac surgery. It is for adults 45 and older who had a heart injury during or after surgery.
New York, New YorkAges 45 years+ - NCT07024160RecruitingPhase 1
First-in-human study of MT1011 injection in healthy volunteers
This trial tests a new medicine called MT1011 given as an injection. Researchers want to see how safe it is and how the body handles it. Healthy people can join to help find the right dose for future studies.
Beijing, Beijing MunicipalityAges 18–45 - NCT07318610RecruitingPhase 3
Study of a new blood thinner in people with leg artery disease
This trial tests if a new blood-thinning drug (factor XI inhibitor) can prevent serious heart and leg problems in people who recently had a leg artery procedure. It compares the new drug to standard care for up to 3 years.
Alexander City, AlabamaAges 18 years+ - NCT05701917Recruiting
Clot-busting device versus blood thinners for leg clot
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT04258488RecruitingPhase 4
Blood thinner pill vs warfarin after mechanical aortic valve
This study compares a blood thinner pill (a factor Xa inhibitor) with warfarin (vitamin K antagonist) in people who have had a mechanical aortic valve replacement. It looks at which option works better and is safer over the long term.
Bucheon-siAges 19 years+ - NCT04262492Recruiting
Registry of adults with APS on blood thinners
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
NancyAges Any age - NCT04263038RecruitingPhase 4
Watchful waiting versus blood thinners for small lung clots
This trial compares close monitoring (“watch and wait”) versus taking the blood thinner rivaroxaban in people with a small type of lung blood clot. It aims to find out whether low-risk patients can safely avoid or reduce anticoagulation while still staying healthy.
Woluwe-Saint-Lambert, Brussels CapitalAges 18 years+ - NCT04694248Recruiting
Blood thinner plus antiplatelet after iliac vein stent
This trial looks at whether taking a blood thinner and an additional clot-prevention medicine (antiplatelet) after iliac vein stenting can improve treatment of certain deep vein clots. It may help prevent the clot from coming back or spreading, but it also increases bleeding risk, so careful eligibility screening is important.
Hangzhou, ZhejiangAges 18 years+ - NCT05029063RecruitingPhase 3
Rivaroxaban to prevent clots in cancer patients with new catheters
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
Halifax, Nova ScotiaAges 18 years+ - NCT05353140Recruiting
Left atrial appendage device vs blood thinners after stent
This trial compares a heart device that can help prevent blood clots in the heart (called LAAO) versus long-term blood thinners for people who have atrial fibrillation and recently had a stent placed. It aims to see which approach better prevents stroke and related blood-clot problems while keeping side effects manageable.
Xi'an, ShannxiAges 18 years+ - NCT05735639RecruitingPhase 4
Prevention of blood clots during varicose vein treatment
This trial tests whether giving medicine to prevent blood clots during varicose vein treatment is safe and helpful. It focuses on people having a minimally invasive procedure on enlarged leg veins under local anesthesia.
LondonAges 18 years+ - NCT05775965RecruitingPhase 2
Aspirin plus rivaroxaban to prevent clots after hip fracture surgery
This trial studies which pill regimen helps prevent dangerous blood clots after hip fracture surgery. You might be eligible if you’re 50 or older and can start treatment soon after your injury.
Calgary, AlbertaAges 50 years+ - NCT05794399RecruitingPhase 4
Blood thinner after heart attack with clot seen on MRI
This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.
Kathmandu, BagmatiAges 18 years+ - NCT05892042Recruiting
Anticoagulant treatment for a heart clot after a heart attack
This trial studies whether a specific blood thinner can better treat a left-side heart clot found soon after a heart attack. It may help prevent the clot from getting worse or causing complications.
Changchun, JilinAges 18–80 - NCT06013020RecruitingPhase 4
Blood thinner to prevent heart clots after a heart attack
This trial tests a blood thinner, rivaroxaban, to see if it can prevent blood clots from forming in the heart after a specific type of heart attack (STEMI) that affects the front part of the heart.
Zunyi, GuizhouAges 18–75 - NCT06194617Recruiting
Rivaroxaban for older Chinese patients with blood clots in lungs
This trial tests whether a blood thinner called rivaroxaban (a pill) works well for older Chinese patients who have had a blood clot in their lungs and are now on long-term treatment. It aims to see if it's safe and effective for this group.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06216769Recruiting
Pill-in-the-pocket blood thinners after AF ablation
This study tests a 'pill-in-the-pocket' approach for blood thinners after a catheter ablation for atrial fibrillation. Instead of taking a daily blood thinner, you may only take it when needed, which could reduce the risk of bleeding while still preventing strokes.
SeoulAges 19–89 - NCT06232551Recruiting
Hospital alert to prescribe rivaroxaban to prevent blood clots
This trial tests whether alerting your hospital doctor to prescribe a blood thinner called rivaroxaban (Xarelto) at discharge can help prevent dangerous blood clots in your legs or lungs. It is for patients who are at higher risk for clots but have a low bleeding risk.
Murray, UtahAges 18–110 - NCT06362343Recruiting
Personalized dosing study for Xa inhibitor blood thinners
This study looks at how the body processes a certain type of blood thinner (Xa factor inhibitors) to help doctors find the right dose for each person. If you have a blood clot in your lungs and are on long-term treatment, this trial might help improve your care.
Beijing, Beijing MunicipalityAges 18–120 - NCT06780462RecruitingPhase 3
Steroids with or without blood thinners for Behçet's vein clots
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
BordeauxAges 18 years+
Common questions
- Are there clinical trials studying Rivaroxaban?
- Yes. Clin2 currently lists 56 recruiting studies that include Rivaroxaban, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Rivaroxaban trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Rivaroxaban an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Rivaroxaban or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.